New Pharmaceuticals research report from Datamonitor is now available from Fast Market Research
Boston, MA -- (SBWIRE) -- 10/25/2012 -- This analysis evaluates the company's strategy and key strengths, weaknesses, opportunities and threats, and provides an overview of the company's historical and forecast financial performance. The report also gives an in-depth analysis of the company's key prescription pharmaceutical product, and provides a forecast sales performance for this drug.
- Patient-based forecasts for Onyx's lead pipeline candidate, Kyprolis (carfilzomib), supported by key opinion leader research
- Assessment of Onyx's corporate strategy, operating performance, and earlier-stage pipeline
View Full Report Details and Table of Contents
In July 2012, the FDA granted accelerated approval for Onyx's proteasome inhibitor Kyprolis for the treatment of patients with multiple myeloma who have received at least two prior therapies including Celgene's Velcade and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Onyx expects to file Kyprolis for approval in the EU in 2013 based on the results of the Phase III ASPIRE trial.
Reasons to Get this Report
- Evaluate the prospects for Onyx's three key products: Kyprolis, Nexavar, and regorafenib
- Assess hematologist-oncologists' views in anticipation of Kyprolis's launch
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- Onyx Pharmaceuticals, Inc. (ONXX) - Financial and Strategic SWOT Analysis Review
- Onyx Pharmaceuticals, Inc. (ONXX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Onyx Pharmaceuticals, Inc.: Company Profile and SWOT Analysis
- Bayer AG (BAYN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Onyx Pharmaceuticals, Inc.: Pharmaceuticals and Healthcare Company Profile, SWOT & Financial Report
- Bayer HealthCare Pharmaceuticals - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Expression Analysis, Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
- Alexza Pharmaceuticals, Inc. (ALXA) - Financial and Strategic SWOT Analysis Review
- Oramed Pharmaceuticals, Inc. (ORMP) - Financial and Strategic SWOT Analysis Review
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)